Release Notes

Discover what's new
in nQuery

Version 9.7

From fixed to flexible trial designs,
nQuery 9.7 is a major update of nQuery to help biostatisticians and clinical researchers save costs and reduce risk.


Multiple Comparisons, additional Group Sequential boundary options and plots, sample size allocation calculations for multi-regional clinical trials and equivalence for variances are highlights of our latest update.

Highlights include:

Whats New in nQuery 9.7 (1)

nQuery 9.7 Release Notes


 

nQuery Pro Tier

What's new in the PRO tier of nQuery 9.7?

1 new sample size + two major feature updates have been added to the Pro tier in nQuery 9.7

  • Multiple Comparisons for Continuous Endpoint (1 Table)
  • 3 Additional Custom Boundary Input Scales for Group Sequential
  • Additional and Improved Plots for Survival Group Sequential

 

1. Multiple Comparisons

 

What is it?

Multi-arm trials which evaluate multiple treatment arms or doses simultaneously within a single protocol are common across multiple stages of clinical research. By avoiding the duplication of control arms, designs which include multiple arms can reduce the cost of evaluating multiple candidate treatment options significantly. However, appropriate statistical methods are required to ensure that Type I error is controlled when evaluating multiple treatments or doses. One class of statistical methods used for this purpose is Multiple Comparisons Procedures.

 

Multiple Comparisons Procedures share the common objective of controlling the Type I error when comparing multiple arms. However, a wide range of potential multiple comparison procedures are available depending on trial design and analysis aspects such as which comparisons will be made (e.g. all arms vs all arms, control arm vs treatment arms only), definition of error control (e.g. Family-Wise Error Rate (FWER), False Discovery Rate (FDR)) or arm testing sequence (e.g. simultaneous, step-up/step-down algorithms).

 

nQuery’s new multiple comparisons table features 14 multiple comparison procedures across five main types:

  • Single-step (Bonferroni, Weighted Bonferroni, Sidak, Dunnetts, Unadjusted),

  • Step-up (Dunnetts, Hochberg),

  • Step-down (Dunnetts, Holm-Bonferroni, Holm-Sidak),

  • Stepwise (Fixed Sequence, Fallback)

  • FDR-based (Benjamini-Hochberg, FDR Benjamini-Yekutieli).

These methods can be used to find the sample size for three definitions of power for a multiple comparisons study: conjunctive power (all arms significant), disjunctive power (at least one arm significant) and marginal power (specific arm significant).

 

nQuery also contains seven algorithms for sample size allocation across the arms: equal allocation across all arms, equal allocation for treatment arms only (with shared sample size ratio to control arm), root K (sample size ratio in each treatment arm equals square root of number of treatment arms), three optimality criteria which minimize variance (A, D, E Optimality available) and custom (specify separate sample size ratio per treatment arm)


nQuery 9.7 adds a multiple comparisons table for a continuous endpoint using analytic formulae. Future updates will extend to additional endpoints (binary, count, survival) and simulation-based methods.

Multiple Comparisons (MGE6)
 Tables added: 

 

  • Multiple Comparisons Procedure - Multiple Arms Single Stage Non-inferiority /Supersuperiority Tests for Means

 

Multiple Comparisons Summary:

  • 14 Multiple Comparisons Procedures:

    • Unadjusted, Bonferroni, Weighted Bonferroni, Sidak, Single-Step Dunnett, Step-Up Dunnett, Step-Up Hochberg, Step-Down Dunnett, Step-Down Holm-Bonferroni, Step-Down Holm-Sidak, Stepwise Fixed Sequence Testing, Stepwise Fallback Procedures, FDR Benjamini-Hochberg, FDR Benjamini-Yekutieli

  • 3 Target Power Definitions:

    • Conjunctive, Disjunctive, Marginal

  • 7 Sample Size Allocation Methods:

    • Equal Across All Arms, Equal Across Treatment Arms, Root K, A-Optimality, D-Optimality, E-Optimality, Custom


2. Group Sequential Design Update: Additional Custom Boundaries

 

What is it?

Group Sequential Design is the most common adaptive design used in confirmatory clinical trials. This design allows trialists to stop a trial early at pre-specified interim analyses if there is sufficient evidence that treatment is effective (efficacy) or ineffective (futility). Group sequential designs capacity to stop trials early can lead to significant cost savings while also getting vital treatments into the hands of patients faster.

 

Over recent releases, nQuery has added an overhauled set of group sequential tables which provide access to a wide suite of boundary methods plus reporting and plotting options. Based on industry best practice and user feedback, we continue to improve our group sequential offering while also adding group sequential tables for additional design scenarios.

 

nQuery offers unparalleled ability to specify a custom group sequential design by providing the Custom Boundary method which allows users to enter their own custom Efficacy and/or Futility boundaries on a variety of parameterization scales including Z-statistic, p-value, Score Statistic, Effect Size and Conditional Power (futility only).

 

In nQuery 9.7, the ability to calculate Conditional Power for a custom “true” effect size assumption was added, in addition to the following three new custom boundary scales:

  • B-value

  • Predictive Power (futility only)

  • Reverse Conditional Power (futility only)

 

The B-value is an independent increments statistic for monitoring (equal to the Z-statistic times the square root of information time) which maps to Brownian motion. The B-value simplifies conditional power calculations and has more stable behavior than the Z-statistic at early looks.

 

In addition, we also extend our custom conditional power boundary option where in addition to specifying the true effect size under the specified effect size (used for power calculation) or estimate effect size (at futility boundary), the user can now set a custom value for the true effect size directly.

Custom GST Bound (Custom CP In Context)-1

 

Predictive Power is an extension of conditional power where instead of assuming a point estimate for the assumed “true” effect size, the conditional power function is averaged over the posterior distribution at an interim analysis, providing a more balanced assessment of the expected power. nQuery offers the option to calculate predictive power under an uninformative uniform prior or a user specified normal prior.

Custom GST Bound (Predictive Power Side-table only)-1

 

Reverse conditional power (also known as inverse conditional power) is an extension of conditional power which shifts from “expected power given current interim data” to “if trial will succeed, how likely is current interim data”. A major advantage is that reverse conditional power removes the requirement for an assumed “true” effect size by conditioning on the final known alpha threshold instead.

 

Custom GST Bound (Reverse CP In Context)-1

Features Added:

  • 3 Additional Custom Boundary Input Parameterizations:
    • B-values, Predictive Power (Futility Only - Uniform or Normal Prior), Reverse Conditional Power (Futility Only)
  • Custom Effect Size option for Conditional Power Custom Boundary

3. Group Sequential Design: Additional Survival Plots

 

What is it?

nQuery currently offers plots for the group sequential boundaries and error spending (i.e. exit probability) function across all of our group sequential tables. However, survival analysis is a more complex endpoint (due to having to model expected events, sample size and dropout) and therefore plots specifically for survival analysis can provide additional insights on important outcomes such as interim analysis timing.

In nQuery 9.7, we add two additional plots specifically for our survival analysis group sequential tables:

  • Sample Size/Events vs Time

  • Survival % vs Follow-up Time

These two plots are also added to the fixed term survival analysis table:
STT37 - Two Sample Log-Rank Test (Event Driven or Fixed Follow-up, Piecewise Accrual %, Hazard Rates + Dropout Rates).

 

Sample Size/Events vs Time plots the total sample size, total events and pre-group events expected under the alternative hypothesis at a given time after study start. This plot provides a practical insight into the expected trajectory of your trial and where you can expect its status to be at the interim and final analyses.

GST Survival Plot (Sample Size Events vs Time in-context)

 

Survival % vs Follow-up Time plots the percentage of subjects expected to survive under the specified hazard rates after a given length of follow-up time after subject entry. This plot provides an insight into the survival pattern expected in your trial which is particularly valuable for more complex piecewise hazard rate patterns.

GST Survival Plot (Survival vs Time)

 

Tables Added:

  • Sample Size/Events vs Time Plots for Survival Tables (GST3, GST5, STT37)
  • Survival % vs Follow-up Time Plots for Survival Tables (GST3, GST5, STT37)

How to update?

If you have a subscription for the nQuery Pro Tier nQuery should automatically prompt you to update. You can manually update nQuery by clicking Help>Check for updates. 

To discuss any aspect of your subscription, click here.

 


 

nQuery Base Tier

 

What's new in the Base tier of nQuery 9.7?

8 new sample size tables have been added to the Base tier of nQuery 9.7

 

  • Multi-Regional Clinical Trials (3 Tables)
  • Vaccines (1 Table)
  • Bioequivalence (4 Tables)


4. Multi-Regional Clinical Trials

 

What is it?

Multi-regional clinical trials (MRCT) are trials which are conducted in multiple regions under a single study protocol. They have rapidly grown in usage as they offer the potential for substantial savings in time and money by providing sufficient evidence for regulatory approval in multiple regions based on a single high-quality confirmatory clinical trial compared to the traditional approach of multiple confirmatory trials plus the potential requirement for additional bridging studies for approval in specific jurisdictions.

 

Due to their popularity, there has been a growth in regulatory guidance for MRCT. One consideration that was of concern to regulators was how to allocate sample size across regions appropriately such that the results would be generalizable to their region of interest. Two sample size criteria were defined by the Japanese regulator (PMDA) to establish the allocation required in the Japan region if approval was sought using an MRCT. These were then integrated into the five options included in the landmark ICH E17 Guidance (2017) as the “Preservation of Effect” and “Local Significance” criteria for sample size allocation across regions.

 

nQuery 9.7 extends our additions for MRCT in nQuery 9.6 by applying the Preservation of Effect approach to the Survival Analysis endpoint and providing two tables for the Sensitivity Index approach for bridging studies, an additional study conducted in a specific region for approval specifically in that region.

 

MRCT (Survival MRCT)

 

Tables Added:

  • Sample Size for a Specific Region in a Multi-Regional Clinical Trial 
  • (MRCT) using Log-Rank Test (PMDA Method One - Preservation of Effect)
  • Sensitivity Index for Bridging Study
  • t-test for Two Means in a Bridging Study using the Sensitivity Index


5. Vaccine Studies

 

What is it?

Vaccines are one of the most successful medical innovations in clinical history. However the unique nature of vaccines where they are provided to entire populations rather than just patients with the disease of interest provides unique challenges when designing clinical trials. Therefore, trial design considerations such as sample size need to integrate these challenges to ensure optimal trial outcomes.

 

Vaccine efficacy is the primary target in clinical trials and the basis for most new vaccine approvals. But there is interest in designs for vaccine efficacy beyond the most common two-arm parallel design.

 

nQuery 9.7 builds on the major additions in vaccine studies in nQuery 9.5 and nQuery 9.6 by adding a table for vaccine efficacy in the multi-arm scenario using a cluster randomized design.

Vaccine (Multiple VE CRT)


Tables Added:

  • Multi-Arm Non-Inferiority/Supersuperiority Tests for Vaccine Efficacy using the Ratio of Vaccine and Control Proportions in a Cluster-Randomized Design

 

6. Bioequivalence

 

What is it?

Bioequivalence testing is the most common route for the approval of new generic medicines. This testing consists of evaluating if the pharmacokinetics (PK) parameters Area under the Curve (AUC) and maximum concentration (Cmax) are equivalent using the two one-sided tests (TOST) or (equivalent) confidence interval approach.

While bioequivalence testing is most often associated with cross-over designs and the PK parameters, it can also be applied for a wide variety of other designs (parallel, repeated measures) and endpoints (binary, survival, variances).

nQuery 9.7 extends our major bioequivalence upgrades in nQuery 9.5 and nQuery 9.6 by adding four tables for equivalence testing of variance measures for parallel, repeated measures and crossover designs.


Example of  Bioequivalence (Variance Parallel)

Bioequivalence (Variance Parallel)


Example of Bioequivalence (Variance Repeated)
Bioequivalence (Variance Repeated)


Table Added:

  • Equivalence F-test for the Ratio of Two Variances 
  • Equivalence F-test for the Ratio of Two Within-Subject Variances 
  • Equivalence F-test for the Ratio of Two Within-Subject Variances (Crossover Design) 
  • Equivalence Z-test for the Difference of Two Within-Subject Coefficient of Variations 

nQuery Predict

Accurately predict your key trial milestones. Identify roadblocks and take action to keep your trial on schedule.

nQuery Predict is the most recent module to be added to the nQuery platform for clinical trial design.

Only available in the expert tier, nQuery Predict is a suite of tools that uses current data to project the likely trajectory of future enrollment or event milestones. With the nQuery Predict module, you can make more informed decisions based on real trial data as it becomes available.

Play this short video below for more information about milestone prediction.

Get started with nQuery today

Start for free and upgrade as your team grows

Release Notes